Development of precision genome editing tools for the functional characterization of genetic variants
Active Project Grant Awarded Last action
- Award ID
- R24OD040592
- Recipient
-
Oklahoma Medical Research Foundation UEI NGCNCJ1X6XA4
- Awarding agency
-
Aggregate Financial Assistance Data
National Institutes of Health, Department of Health and Human Services
- Obligated
- $805,745
Award facts
- Assistance listing
- 93.351 Research Infrastructure Programs
- Completion date 10% complete
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- Oklahoma City, OK 73104, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health Office of the Director awarded Oklahoma Medical Research Foundation $805,745 on July 1, 2026, under the Research Infrastructure Programs (CFDA 93.351) to develop precision genome editing tools for functional characterization of genetic variants.
The award funds development of a high-throughput, cost-effective platform for in vivo functional validation of human disease-associated genetic variants using zebrafish as a model organism. The project addresses the challenge that over half of genetic variants identified through clinical sequencing are variants of uncertain significance, limiting accurate genetic diagnosis and patient care. Current genome editing methods lack the efficiency, specificity, and scalability needed for high-throughput functional validation in vivo, with technical barriers including bystander mutations, insertions and deletions, and limited targeting coverage.
The work encompasses three integrated objectives: development of high-fidelity CRISPR base editors with expanded genomic targeting to model single-nucleotide variants with minimal bystander mutations; creation of a deep learning model to design optimized guide RNAs for CRISPR base editing; and engineering next-generation prime and click editors for precise in vivo editing. The platform will accelerate variants of uncertain significance interpretation, reduce diagnostic delays, and be extendable to other aquatic models to advance therapeutic development.
Performance occurs in Oklahoma City, Oklahoma, with period of performance from July 1, 2026, through March 31, 2030. The award is classified as a Project Grant.
Description
- Abstract
- Over half of the genetic variants identified through clinical sequencing are variants of uncertain significance (VUS), posing a significant challenge to accurate genetic diagnosis and effective patient care due to the unknown functional impact of these single-nucleotide variants (SNVS). Current genome editing methods lack the efficiency, specificity, and scalability required for high-throughput functional validation in vivo, presenting challenges such as bystander mutations, insertions/deletions, and limited targeting coverage in zebrafish, an ideal model organism for human disease genetics. This proposal aims to establish a high-throughput, cost-effective platform for in vivo functional validation of human disease-associated genetic variants using the zebrafish model. The central hypothesis is that optimized crispr editors, when paired with zebrafish-specific computational tools, will enable efficient and precise modeling of single-nucleotide variants (SNVS). Three integrated aims will be pursued: (1) develop high-fidelity base editors with expanded genomic targeting to model SNVS with minimal bystander mutations and enhanced editing efficiency; (2) create a deep learning model to design optimized guide rnas for crispr base editing, improving variant editing accuracy; and (3) engineer next-generation prime and click editors for precise in vivo editing. This innovative approach introduces zebrafish-optimized crispr tools, a novel deep learning model, and pioneering click editing, overcoming specificity and scalability barriers. The platform will accelerate VUS interpretation, reduce diagnostic delays, and be extended to other aquatic models, advancing therapeutic development and supporting the goals of PAR-23-039.
Quick answers
Who received award R24OD040592?
R24OD040592 was awarded to Oklahoma Medical Research Foundation by Aggregate Financial Assistance Data (National Institutes of Health) on July 1, 2026.
How much is award R24OD040592 worth?
$805,745 has been obligated on R24OD040592.
Which agency awarded R24OD040592?
Aggregate Financial Assistance Data (National Institutes of Health) awarded R24OD040592, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award